PURPOSE: To investigate the association between external beam radiotherapy (EBRT) dose and biochemical failure (BcF) of prostate cancer in patients who received salvage prostate bed EBRT for a rising prostate-specific antigen (PSA) level after radical prostatectomy. METHODS AND MATERIALS: We evaluated patients with a rising PSA level after prostatectomy who received salvage EBRT between July 1987 and October 2007. Patients receiving pre-EBRT androgen suppression were excluded. Cox proportional hazards models were used to investigate the association between EBRT dose and BcF. Dose was considered as a numeric variable and as a categoric variable (low, <64.8 Gy; moderate, 64.8-66.6 Gy; high, >66.6 Gy). RESULTS: A total of 364 men met study selection criteria and were followed up for a median of 6.0 years (range, 0.1-19.3 years). Median pre-EBRT PSA level was 0.6 ng/mL. The estimated cumulative rate of BcF at 5 years after EBRT was 50% overall and 57%, 46%, and 39% for the low-, moderate-, and high-dose groups, respectively. In multivariable analysis adjusting for potentially confounding variables, there was evidence of a linear trend between dose and BcF, with risk of BcF decreasing as dose increased (relative risk [RR], 0.77 [5.0-Gy increase]; p = 0.05). Compared with the low-dose group, there was evidence of a decreased risk of BcF for the high-dose group (RR, 0.60; p = 0.04), but no difference for the moderate-dose group (RR, 0.85; p = 0.41). CONCLUSIONS: Our results suggest a dose response for salvage EBRT. Doses higher than 66.6 Gy result in decreased risk of BcF. Copyright (c) 2010 Elsevier Inc. All rights reserved.
PURPOSE: To investigate the association between external beam radiotherapy (EBRT) dose and biochemical failure (BcF) of prostate cancer in patients who received salvage prostate bed EBRT for a rising prostate-specific antigen (PSA) level after radical prostatectomy. METHODS AND MATERIALS: We evaluated patients with a rising PSA level after prostatectomy who received salvage EBRT between July 1987 and October 2007. Patients receiving pre-EBRT androgen suppression were excluded. Cox proportional hazards models were used to investigate the association between EBRT dose and BcF. Dose was considered as a numeric variable and as a categoric variable (low, <64.8 Gy; moderate, 64.8-66.6 Gy; high, >66.6 Gy). RESULTS: A total of 364 men met study selection criteria and were followed up for a median of 6.0 years (range, 0.1-19.3 years). Median pre-EBRT PSA level was 0.6 ng/mL. The estimated cumulative rate of BcF at 5 years after EBRT was 50% overall and 57%, 46%, and 39% for the low-, moderate-, and high-dose groups, respectively. In multivariable analysis adjusting for potentially confounding variables, there was evidence of a linear trend between dose and BcF, with risk of BcF decreasing as dose increased (relative risk [RR], 0.77 [5.0-Gy increase]; p = 0.05). Compared with the low-dose group, there was evidence of a decreased risk of BcF for the high-dose group (RR, 0.60; p = 0.04), but no difference for the moderate-dose group (RR, 0.85; p = 0.41). CONCLUSIONS: Our results suggest a dose response for salvage EBRT. Doses higher than 66.6 Gy result in decreased risk of BcF. Copyright (c) 2010 Elsevier Inc. All rights reserved.
Authors: A Karl; A Buchner; C Tympner; T Kirchner; U Ganswindt; C Belka; R Ganzer; M Burger; F Eder; F Hofstädter; D Schilling; K Sievert; A Stenzl; M Scharpf; F Fend; F Vom Dorp; H Rübben; K Schmid; D Porres-Knoblauch; A Heidenreich; B Hangarter; R Knüchel-Clarke; M Rogenhofer; B Wullich; A Hartmann; E Comploj; A Pycha; E Hanspeter; D Pehrke; G Sauter; M Graefen; C Stief; A Haese Journal: World J Urol Date: 2015-02-15 Impact factor: 4.226
Authors: Tim J Kruser; David F Jarrard; Andrew K Graf; Sean P Hedican; David R Paolone; John D Wegenke; Glenn Liu; Heather M Geye; Mark A Ritter Journal: Cancer Date: 2010-12-14 Impact factor: 6.860
Authors: Alessandra Siegmann; Dirk Bottke; Julia Faehndrich; Gunnar Lohm; Kurt Miller; Detlef Bartkowiak; Thomas Wiegel; Wolfgang Hinkelbein Journal: Strahlenther Onkol Date: 2011-07-22 Impact factor: 3.621
Authors: Thomas M Pisansky; Ian M Thompson; Richard K Valicenti; Anthony V D'Amico; Shalini Selvarajah Journal: J Urol Date: 2019-08-08 Impact factor: 7.450